New patents approved and international agreement for PharmaNutra

The Group obtains approval of two new patents for the Sucrosomial^® Technology and signs a distribution agreement for the SiderAL^® line products in Finland.

PharmaNutra S.p.A., obtains further important scientific and commercial results, thanks to the strengthening of its strategic assets and position on international markets.
While the effectiveness of the Sucrosomial^® Technology was being officially acknowledged in Israel, which granted the Solid Iron patent (Patent Application number 236793) to be valid until 30ᵗʰ July 2033, the Group’s Scientific Department, managed by Germano Tarantino, achieved another important result.

The Italian Patent Office has granted PharmaNutra an important patent, for a new composition to be used in preventing and treating the lack of iron. The new patent joins the Sucrosomial^® Iron based formulas that have made the company a leader in the nutritional supplements sector. This composition was developed specifically to treat the chronic lack of iron in certain areas, where there is an ongoing condition resulting from or concurrent with gastroenterological problems, or of another kind (nephrology, haematology) mainly affecting the geriatric population.

 
“This new patent is a truly important result for our company, added to those obtained in the last few months”, declares the President of PharmaNutra S.p.A. Andrea Lacorte. “More specifically, we are talking about a discovery with really high scientific value. Once again confirming how important research is for us. A value PharmaNutra was founded on and that enables us to keep on growing month after month. Our work is to find innovative solutions for problems troubling broad segments of the population. A commitment that will be even more important and concrete with the Group’s new production and R&D offices”.

 
Strengthening assets does not just involve the Group’s scientific division: PharmaNutra recently signed a new distribution agreement for SiderAL^® line products in Finland. The agreement, signed with Sabora Pharma OY, foresees the launch of two Sucrosomial^® Iron products of the Adult line on the local market (SiderAL^® Folic 30 mg Sucrosomial^® Iron 20 stick/box and SiderAL^® Forte 30 mg Sucrosomial^® Iron 20 cps/box), strengthening the SiderAL^® brand position on markets in Northern Europe.